Literature DB >> 372220

Evaluation of colistin and nalidixic acid in Todd-Hewitt broth for selective isolation of group B streptocci.

L J Fenton, M H Harper.   

Abstract

Todd-Hewitt broth (THB) containing colistin and nalidixic acid was compared with four other media with respect to efficacy of isolation of group B streptocci. It was effective as plain THB, THB with gentamicin and nalidixic acid and blood, and THB with colistin, nalidixic acid, and blood. THB with gentamicin and nalidixic acid, but without blood, was inhibitory to group B streptocci. The value of THB with colistin and nalidixic acid lies in its ability to successfully inhibit gram-negative organisms and still promote group B streptococcal growth without the addition of blood. This greatly reduces the time and expense of media preparation and permits early determination of bacterial growth, so that other means of rapidly identifying group B streptocci can be applied at the earliest possible time.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 372220      PMCID: PMC272983          DOI: 10.1128/jcm.9.2.167-169.1979

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  7 in total

1.  Transmission of group B streptococci among parturient women and their neonates.

Authors:  C J Baker; F F Barrett
Journal:  J Pediatr       Date:  1973-12       Impact factor: 4.406

2.  Selective broth medium for isolation of group B streptococci.

Authors:  C J Baker; D J Clark; F F Barrett
Journal:  Appl Microbiol       Date:  1973-12

Review 3.  Summary of the workshop on perinatal infections due to group B Streptococcus.

Authors: 
Journal:  J Infect Dis       Date:  1977-07       Impact factor: 5.226

4.  Selective and enhanced recovery of group A and B streptococci from throat cultures with sheep blood agar containing sulfamethoxazole and trimethoprim.

Authors:  B A Gunn; D K Ohashi; C A Gaydos; E S Holt
Journal:  J Clin Microbiol       Date:  1977-06       Impact factor: 5.948

5.  Evaluation of four methods for detection of group B streptococcal colonization.

Authors:  E O Mason; P Wong; F F Barrett
Journal:  J Clin Microbiol       Date:  1976-11       Impact factor: 5.948

6.  Nosocomial transmission of group B streptococci.

Authors:  R C Aber; N Allen; J T Howell; H W Wilkenson; R R Facklam
Journal:  Pediatrics       Date:  1976-09       Impact factor: 7.124

7.  Distribution by serological type of group B streptococci isolated from a variety of clinical material over a five-year period (with special reference to neonatal sepsis and meningitis).

Authors:  H W Wilkinson; R R Facklam; E C Wortham
Journal:  Infect Immun       Date:  1973-08       Impact factor: 3.441

  7 in total
  6 in total

1.  Prevention of perinatal group B streptococcal infection: Management strategies.

Authors:  N N Demianczuk; S A Halperin; D D McMillan
Journal:  Can J Infect Dis       Date:  1997-03

2.  Elimination of multiple reactions of the Phadebact Streptococcus coagglutination test.

Authors:  D E Jones; K S Kanarek; J L Angel; D V Lim
Journal:  J Clin Microbiol       Date:  1983-09       Impact factor: 5.948

3.  Use of Granada medium to detect group B streptococcal colonization in pregnant women.

Authors:  M Rosa-Fraile; J Rodriguez-Granger; M Cueto-Lopez; A Sampedro; E B Gaye; J M Haro; A Andreu
Journal:  J Clin Microbiol       Date:  1999-08       Impact factor: 5.948

4.  Screening pregnant women for group B streptococcal colonization.

Authors:  T A Madani; G K Harding; M Helewa; M J Alfa
Journal:  Infection       Date:  1998 Sep-Oct       Impact factor: 3.553

5.  Faecal carriage of group B streptococci.

Authors:  K M Persson; B Bjerre; L Elfström; S Polberger; A Forsgren
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

6.  Rapid identification of pregnant women heavily colonized with group B streptococci.

Authors:  D E Jones; E M Friedl; K S Kanarek; J K Williams; D V Lim
Journal:  J Clin Microbiol       Date:  1983-09       Impact factor: 5.948

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.